Evotec and Apeiron Biologics to Discover Novel Pain Therapeutics

17-Feb-2006

Evotec AG and Apeiron Biologics GmbH announced that they have entered into a discovery collaboration to develop small molecules targeting a novel therapeutic concept for pain relief. This concept is based on research activities of Prof Josef Penninger, Director of the Institute for Molecular Biotechnology of the Austrian Academy of Sciences (IMBA).

During the initial phase of this collaboration, Apeiron Biologics and Evotec will jointly develop tailored biochemical and cellular assays, and Evotec will apply its skills in utilising such assays for ultra-high-throughput screening to identify promising hit molecules. At a later stage, both companies aim at advancing a selected lead compound into preclinical development up to proof-of-concept in patients. Commercialisation rights which are shared equally may be out-licensed or assigned to a pharma partner.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances